Scrip
Affimed spins out discovery capabilities as it approaches the clinic
14 January 2010
Sukaina Virji
Please Login to read the full article.
14 January 2010
Sukaina Virji
Affimed Therapeutics, a German therapeutic antibody company, is to focus all of its activities on the development of its in-house drug candidates. As a result, it has spun out its antibody discovery capabilities into a new company, AbCheck, based in the Czech Republic.
Affimed will now concentrate...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sustained release Aricept and eribulin key near-term R&D projects for Eisai
- Seattle Genetics taps Takeda as partner for lead antibody-drug conjugate
- Gloucester gets first drug approval in US with Istodax for rare lymphoma
- Trubion and Facet to develop TRU-016 in A $207 million deal
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
